

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, Item 5 below. ACTION	
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/GB 00/ 01000	17/03/2000	17/03/1999
Applicant		
BIODIVERSITY LIMITED et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the language, the International search was carried out on the basis of the International application in the language in which it was filed, unless otherwise indicated under this item.

the International search was carried out on the basis of a translation of the International application furnished to this Authority (Rule 23.1(b)).

b. With regard to any nucleotide and/or amino acid sequence disclosed in the International application, the International search was carried out on the basis of the sequence listing :

contained in the International application in written form.

filed together with the International application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the International application as filed has been furnished.

the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. Certain claims were found unsearchable (See Box I).

3. Unity of invention is lacking (see Box II).

4. With regard to the title,

the text is approved as submitted by the applicant.

the text has been established by this Authority to read as follows:

5. With regard to the abstract,

the text is approved as submitted by the applicant.

the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

as suggested by the applicant.

because the applicant failed to suggest a figure.

because this figure better characterizes the invention.

13

None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No

P B 00/01000

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C12M1/12 C12M1/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPODOC WPI PAJ TXTE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2 761 813 A (A. GOETZ) 4 September 1956 (1956-09-04)	1,6, 8-10, 12, 13, 15, 16, 20, 25-31
Y	column 2, line 24 -column 3, line 73 column 5, line 21 - line 42; claims; figures 1-6 --- -/-	14, 17-19, 21-24

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the International search

31 May 2000

Date of mailing of the International search report

07/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentiaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Coucke, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/01000

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2 923 669 A (E. POITRAS) 2 February 1960 (1960-02-02)	1, 6, 8-10, 12, 13, 15, 16, 20, 25-31
Y	the whole document column 3, line 50 - line 68 ---	14, 17-19, 21-24
X	US 3 448 011 A (RUSSOMANNO ROCCO JOSEPH) 3 June 1969 (1969-06-03)	1, 14, 17-19, 21-24, 26, 27, 29-31
Y	column 6, line 19 -column 7, line 7; figures ---	1, 14, 17-19, 21-24, 26
X	EP 0 236 751 A (SARTORIUS GMBH) 16 September 1987 (1987-09-16) claims; figures ---	26, 27, 29-31
X	US 5 122 470 A (BANES ALBERT J) 16 June 1992 (1992-06-16) claims; figures ---	26-29
X	US 5 324 657 A (TANNY GERALD B) 28 June 1994 (1994-06-28) claims; figures ---	26-29
X	PATENT ABSTRACTS OF JAPAN vol. 1996, no. 08, 30 August 1996 (1996-08-30) & JP 08 089231 A (KIKKOMAN CORP), 9 April 1996 (1996-04-09) abstract ---	26-29
X	US 5 215 920 A (LYMAN GEORGE ET AL) 1 June 1993 (1993-06-01) claims; figures ---	26, 27, 29
X	DE 839 245 C (E KANZ) page 4, line 33 - line 45; claims; figure 3 ---	26-31
X	EP 0 390 367 A (STERIS CORP) 3 October 1990 (1990-10-03) figures ---	26, 27, 29
X	US 4 772 558 A (HAMMANN RANIER) 20 September 1988 (1988-09-20) figures ---	26, 27, 29-31
		-/-

INTERNATIONAL SEARCH REPORT

International Application No.

GB 00/01000

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR 2 070 560 A (GUIGAN JEAN) 10 September 1971 (1971-09-10) figures ---	26,27, 29,31
Y	US 5 879 932 A (SPAULDING VINCENT P ET AL) 9 March 1999 (1999-03-09) claims; figures ---	1,26
X	US 4 859 586 A (EISENBERG ELIAHU ET AL) 22 August 1989 (1989-08-22) claims; figures ---	26,27, 29-31
X	EP 0 581 022 A (DIESSE DIAGNOSTICA) 2 February 1994 (1994-02-02) claims; figures -----	26,27, 29-31
Y		1,14, 17-19, 21-24

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/01000

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
US 2761813	A 04-09-1956	NONE			
US 2923669	A 02-02-1960	NONE			
US 3448011	A 03-06-1969	NONE			
EP 0236751	A 16-09-1987	DE	3703608 A	13-08-1987	
		DE	3744925 C	19-12-1991	
		DE	3744926 C	28-11-1991	
US 5122470	A 16-06-1992	AU	3865489 A	05-02-1990	
		EP	0435871 A	10-07-1991	
		JP	4500455 T	30-01-1992	
		WO	9000595 A	25-01-1990	
US 5324657	A 28-06-1994	IL	101659 A	30-03-1995	
		IL	105209 A	31-01-1996	
		AT	162927 T	15-02-1998	
		CA	2159213 A	13-10-1994	
		WO	9422290 A	13-10-1994	
		DE	69408447 D	12-03-1998	
		EP	0692929 A	24-01-1996	
JP 08089231	A 09-04-1996	NONE			
US 5215920	A 01-06-1993	US	5026649 A	25-06-1991	
		US	5466602 A	14-11-1995	
		CA	1333373 A	06-12-1994	
		DE	3686050 A	20-08-1992	
		DE	3686050 T	11-03-1993	
		EP	0239697 A	07-10-1987	
		JP	1815202 C	18-01-1994	
		JP	5017830 B	10-03-1993	
		JP	62220184 A	28-09-1987	
DE 839245	C	NONE			
EP 0390367	A 03-10-1990	US	4885253 A	05-12-1989	
		AT	98989 T	15-01-1994	
		CA	2010063 A, C	27-09-1990	
		DE	69005344 D	03-02-1994	
		DE	69005344 T	21-04-1994	
		DK	390367 T	14-02-1994	
		ES	2047845 T	01-03-1994	
		HK	183896 A	11-10-1996	
		JP	2286073 A	26-11-1990	
		JP	2562221 B	11-12-1996	
US 4772558	A 20-09-1988	NONE			
FR 2070560	A 10-09-1971	CA	969118 A	10-06-1975	
		CH	554939 A	15-10-1974	
		DE	2058300 A	09-06-1971	
		GB	1312280 A	04-04-1973	
		JP	49006671 B	15-02-1974	
		NL	7017605 A, B	11-06-1971	
		SE	385714 B	19-07-1976	
		US	3796638 A	12-03-1974	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/01000

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5879932	A 09-03-1999	NONE		
US 4859586	A 22-08-1989	CH 671031 A		31-07-1989
		DE 8622419 U		22-01-1987
		FR 2586426 A		27-02-1987
		GB 2182144 A, B		07-05-1987
EP 0581022	A 02-02-1994	IT 226753 Z		01-07-1997
		AT 157395 T		15-09-1997
		DE 69313377 D		02-10-1997
		DE 69313377 T		26-02-1998
		ES 2108786 T		01-01-1998
		GR 3025289 T		27-02-1998
		JP 6078746 A		22-03-1994
		US 5420018 A		30-05-1995

INTERNATIONAL SEARCH REPORT

Interr. Application No.
PCT/G/01000

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12M1/12 C12M1/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPODOC WPI PAJ TXTE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	✓ US 2 761 813 A (A. GOETZ) 4 September 1956 (1956-09-04)	1, 6, 8-10, 12, 13, 15, 16, 20, 25-31
Y	column 2, line 24 -column 3, line 73 column 5, line 21 - line 42; claims; figures 1-6 ----- -/-	14, 17-19, 21-24

 Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the International search report

31 May 2000

07/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Coucke, A

INTERNATIONAL SEARCH REPORT

PCT/GB 00/01000

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2 923 669 A (E. POITRAS) 2 February 1960 (1960-02-02)	1, 6, 8-10, 12, 13, 15, 16, 20, 25-31
Y	the whole document column 3, line 50 - line 68	14, 17-19, 21-24
X	✓ US 3 448 011 A (RUSSOMANNO ROCCO JOSEPH) 3 June 1969 (1969-06-03)	1, 14, 17-19, 21-24, 26, 27, 29-31
Y	column 6, line 19 -column 7, line 7; figures	1, 14, 17-19, 21-24, 26
X	EP 0 236 751 A (SARTORIUS GMBH) 16 September 1987 (1987-09-16) claims; figures	26, 27, 29-31
X	✓ US 5 122 470 A (BANES ALBERT J) 16 June 1992 (1992-06-16) claims; figures	26-29
X	✓ US 5 324 657 A (TANNY GERALD B) 28 June 1994 (1994-06-28) claims; figures	26-29
X	✓ PATENT ABSTRACTS OF JAPAN vol. 1996, no. 08, 30 August 1996 (1996-08-30) & JP 08 089231 A (KIKKOMAN CORP), 9 April 1996 (1996-04-09) abstract	26-29
X	✓ US 5 215 920 A (LYMAN GEORGE ET AL) 1 June 1993 (1993-06-01) claims; figures	26, 27, 29
X	✓ DE 839 245 C (E KANZ) page 4, line 33 - line 45; claims; figure 3	26-31
X	✓ EP 0 390 367 A (STERIS CORP) 3 October 1990 (1990-10-03) figures	26, 27, 29
X	✓ US 4 772 558 A (HAMMANN RANIER) 20 September 1988 (1988-09-20) figures	26, 27, 29-31
		-/-

INTERNATIONAL SEARCH REPORT

Intert  Application No
PCT/  0/01000

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	✓ FR 2 070 560 A (GUIGAN JEAN) 10 September 1971 (1971-09-10) figures	26,27, 29,31
Y	✓ US 5 879 932 A (SPAULDING VINCENT P ET AL) 9 March 1999 (1999-03-09) claims; figures	1,26
X	✓ US 4 859 586 A (EISENBERG ELIAHU ET AL) 22 August 1989 (1989-08-22) claims; figures	26,27, 29-31
X	✓ EP 0 581 022 A (DIESSE DIAGNOSTICA) 2 February 1994 (1994-02-02) claims; figures	26,27, 29-31
Y	—	1,14, 17-19, 21-24

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/01000

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 2761813	A	04-09-1956	NONE		
US 2923669	A	02-02-1960	NONE		
US 3448011	A	03-06-1969	NONE		
EP 0236751	A	16-09-1987	DE 3703608 A DE 3744925 C DE 3744926 C	13-08-1987 19-12-1991 28-11-1991	
US 5122470	A	16-06-1992	AU 3865489 A EP 0435871 A JP 4500455 T WO 9000595 A	05-02-1990 10-07-1991 30-01-1992 25-01-1990	
US 5324657	A	28-06-1994	IL 101659 A IL 105209 A AT 162927 T CA 2159213 A WO 9422290 A DE 69408447 D EP 0692929 A	30-03-1995 31-01-1996 15-02-1998 13-10-1994 13-10-1994 12-03-1998 24-01-1996	
JP 08089231	A	09-04-1996	NONE		
US 5215920	A	01-06-1993	US 5026649 A US 5466602 A CA 1333373 A DE 3686050 A DE 3686050 T EP 0239697 A JP 1815202 C JP 5017830 B JP 62220184 A	25-06-1991 14-11-1995 06-12-1994 20-08-1992 11-03-1993 07-10-1987 18-01-1994 10-03-1993 28-09-1987	
DE 839245	C		NONE		
EP 0390367	A	03-10-1990	US 4885253 A AT 98989 T CA 2010063 A,C DE 69005344 D DE 69005344 T DK 390367 T ES 2047845 T HK 183896 A JP 2286073 A JP 2562221 B	05-12-1989 15-01-1994 27-09-1990 03-02-1994 21-04-1994 14-02-1994 01-03-1994 11-10-1996 26-11-1990 11-12-1996	
US 4772558	A	20-09-1988	NONE		
FR 2070560	A	10-09-1971	CA 969118 A CH 554939 A DE 2058300 A GB 1312280 A JP 49006671 B NL 7017605 A,B SE 385714 B US 3796638 A	10-06-1975 15-10-1974 09-06-1971 04-04-1973 15-02-1974 11-06-1971 19-07-1976 12-03-1974	

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte [redacted]inal Application No
PCT/GB [redacted]01000

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
US 5879932	A 09-03-1999	NONE			
US 4859586	A 22-08-1989	CH	671031	A	31-07-1989
		DE	8622419	U	22-01-1987
		FR	2586426	A	27-02-1987
		GB	2182144	A, B	07-05-1987
EP 0581022	A 02-02-1994	IT	226753	Z	01-07-1997
		AT	157395	T	15-09-1997
		DE	69313377	D	02-10-1997
		DE	69313377	T	26-02-1998
		ES	2108786	T	01-01-1998
		GR	3025289	T	27-02-1998
		JP	6078746	A	22-03-1994
		US	5420018	A	30-05-1995


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12M 1/12, 1/26		A1	(11) International Publication Number: WO 00/55297
			(43) International Publication Date: 21 September 2000 (21.09.00)
(21) International Application Number: PCT/GB00/01000		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 17 March 2000 (17.03.00)			
(30) Priority Data: 9906206.9 17 March 1999 (17.03.99) GB 9929385.4 10 December 1999 (10.12.99) GB			
(71) Applicant (for all designated States except US): BIODIVERSITY LIMITED [GB/GB]; Business Innovation Centre, Room 23/24, Innova Park, Mollison Avenue, Enfield, Middlesex EN3 7XU (GB).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): PORTER, Neil [GB/GB]; BioDiversity Limited, Business Innovation Centre, Room 23/24, Innova Park, Mollison Avenue, Enfield, Middlesex EN3 7XU (GB); GIAQUINTO, Frances, Mary [GB/GB]; BioDiversity Limited, Business Innovation Centre, Room 23/24, Innova Park, Mollison Avenue, Enfield, Middlesex EN3 7XU (GB).			
(74) Agents: BERESFORD, Keith, Denis, Lewis et al.; Beresford & Co., 2-5 Warwick Court, High Holborn, London WC1R 5DJ (GB).			

(54) Title: BIOCHEMICAL SYNTHESIS APPARATUS

(57) Abstract

A biochemical synthesis apparatus comprises a receptacle for containing a medium, and a support on which a microorganism can be placed. The support can be placed in contact with the medium, so as to allow access of the microorganism to the medium. The support with the microorganism can be removed from the medium, allowing the medium to be replaced. By this, the receptacle can firstly contain a growth medium, and secondly a secondary medium capable of causing the production by the microorganism of a potentially useful biochemical.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

BIOCHEMICAL SYNTHESIS APPARATUS

5 The present invention is concerned with apparatus for use in a biochemical reaction of a microorganism, and a process for the synthesis of one or more biochemicals as a result of that biochemical reaction.

10 Microorganisms such as fungi and bacteria produce a vast diversity of chemical species through biochemical pathways which constitute secondary metabolism. Secondary metabolism commences in the absence of one or more nutrients essential to the performance of primary metabolism. While primary metabolites and their metabolism are essential for growth, secondary 15 metabolites by definition are not, but they are believed to contribute to the survival of a microorganism in a number of ways, as set out in "Diversity of Microbial Products - Discovery and Application" by N. Porter and F. M. Fox (1993), Pesticide Science 39, pp 161-168. Secondary metabolites, therefore, often exhibit diverse 20 biological properties and as such can provide the basis of new therapeutic drugs.

25 As a consequence, microorganisms are constantly being studied with a view to finding new and useful secondary.

metabolites. However, commonly used processes for the fermentation and production of samples containing secondary metabolites are often not compatible with the requirements of modern drug screening technologies. In 5 small scale fermentations, secondary metabolism cannot be controlled effectively and many different and often randomly selected nutrient solutions must be used to achieve the specific set of conditions required for secondary metabolism. Additionally, secondary 10 metabolites secreted by the microorganism are diluted and contaminated with complex nutrients present in the growth medium. This can lead to low quality samples for screening.

15 In liquid fermentation, secondary metabolites are currently produced by suspending a sample of the microorganism in a medium consisting of an aqueous solution or suspension of a combination of appropriate nutrients. The suspension is placed in a stoppered flask 20 which allows the ingress of oxygen and the flask is agitated by shaking to mix and aerate the suspension. Growth and primary metabolism of the microorganism occurs until one of the essential nutrients in the medium is exhausted, at which point secondary metabolism commences.

Initially, after inoculating the nutrient medium with microorganism there is often a variable delay or lag period before growth commences. Then, in trophophase, the organism grows in a linear or exponential fashion 5 through primary metabolic processes until the growth rate begins to decrease as an essential nutrient, such as nitrogen or phosphate, becomes exhausted as the organism enters idiophase. At that point, secondary metabolism is induced as a result of a specific nutrient exhaustion and 10 a secondary metabolite is produced.

For an individual microorganism, the lag phase can vary due to, amongst other things, the age and size of the culture inoculum. Replicate cultures, while growing at 15 the same rate, could have different lag phases and therefore could finish growing and enter idiophase at different times.

Moreover, different microorganisms could exhibit similar 20 lag phases but differ significantly in their growth rates so that they consume essential nutrients at different rates, and they finish growing at different times, consequently entering idiophase at different times. The different growth rates could also be exhibited by an 25 individual microorganism growing on different nutrient

containing media.

For high throughput screening of secondary metabolites, samples thereof need to be generated by cultivating 5 microorganisms in large batches. The inability to control secondary metabolism by established processes means that the potential of each organism within a batch to produce new secondary metabolites is not realised because samples are prepared from fermentations after a 10 fixed time period at which it is expected that secondary metabolism will have commenced. However, for the above reasons organisms may not have begun secondary metabolism. Additionally, secreted secondary metabolites will be mixed with complex nutrients from the growth 15 media. These can interfere with the drug screening procedures, making screening less efficient and productive.

Therefore, it is an object of the present invention to 20 provide apparatus and a procedure which allows more predictable production of secondary metabolite samples in a form compatible with the operational requirements of high throughput screening technologies.

25 A first aspect of the invention provides a biological

procedure including arranging biomass with access to a medium, said medium being suitable to support biomass growth, and replacing said medium with a replacement medium suitable to define conditions for secondary metabolism in said biomass.

5 A second aspect of the invention provides a procedure for generating a biochemical including the steps of causing an organism to metabolise in the presence of a first medium for growth of biomass and causing said organism to metabolise in the presence of a second medium for generation of said biochemical.

10 A third aspect of the invention provides a procedure which comprises the steps of growing an organism under conditions of primary metabolism in the presence of excess essential nutrients for growth, separating the organism from the essential nutrients and allowing the organism to metabolise in the absence of essential nutrients under conditions supporting secondary metabolism.

15 A fourth aspect of the invention provides a procedure which comprises the steps of growing an organism under conditions of primary metabolism in the presence of

excess essential nutrients for growth, separating the organism from the essential nutrients and allowing the organism to metabolise in the presence of a reduced concentration of one or more essential nutrients so as to 5 support secondary metabolism.

A fifth aspect of the invention provides a procedure which comprises the steps of growing an organism under conditions of primary metabolism in the presence of 10 excess essential nutrients, separating the organism from the essential nutrients, and placing the organism in conditions supporting secondary metabolism thereby to generate a secondary metabolite.

15 It is an advantage of the invention that secondary metabolites generated in accordance therewith can be secreted into a liquid medium containing no or limited amounts of defined nutrients but substantially free from the complex mixture of essential nutrients required for 20 the growth of the organism.

It is a further advantage of the invention that defined conditions can be selected to induce and support secondary metabolism in a diverse range of 25 microorganisms.

By providing a specific separation step, the exhaustion of an essential nutrient can be carefully controlled, thereby inducing secondary metabolism and controlling the production of secondary metabolites.

5

A sixth aspect of the invention provides a biological procedure including placing biomass with access to a medium formulated for biomass growth, selectively removing said biomass from said medium, and placing said 10 biomass with access to a secondary medium suitable to stimulate an alternative metabolic pathway.

10

A seventh aspect of the invention provides apparatus for arranging a microorganism for metabolism, the apparatus comprising a receptacle for containing a nutrient medium, and a means for supporting a microorganism which allows access to nutrient for metabolism, wherein the means for supporting a microorganism can be selectively separated 15 from the nutrient in use.

20

An eighth aspect of the invention provides apparatus for supporting biomass such that said biomass can be selectively positioned for access to an environment for controlling a biological process in said biomass in use.

25

A ninth aspect of the invention provides a procedure including arranging biomass with access to a medium, said medium being suitable to support biosynthesis with respect to said biomass, and replacing said medium with 5 a replacement medium from which a product of said biosynthesis is distinguishable.

Further aspects and advantages of the present invention will be appreciated from the following description of 10 specific embodiments and examples of the invention, with reference to the accompanying drawings in which:

Figure 1 is a schematic cross-sectional diagram of apparatus in accordance with a first specific embodiment 15 of the invention;

Figure 2 is a perspective view of a raft of the apparatus illustrated in Figure 1;

20 Figure 3 is a perspective view of a fermentation vessel in accordance with the first specific embodiment of the invention;

25 Figure 4 is a cross-sectional view of the fermentation vessel illustrated in Figure 3;

Figure 5 is a cross-sectional view of a fermentation vessel in accordance with a second specific embodiment of the invention;

5 Figure 6 is a schematic diagram of apparatus in accordance with a third specific embodiment of the invention;

10 Figure 7a is a chromatogram for a test sample prepared in accordance with a first example of a specific method in accordance with the present invention;

15 Figure 7b is a chromatogram for a control sample illustrated for comparison with the chromatogram of Figure 7a;

Figure 8a is a chromatogram for a first test sample prepared in accordance with a second example of a specific method in accordance with the present invention;

20 Figure 8b is a chromatogram for a second test sample prepared in accordance with a second example of a specific method in accordance with the present invention;

25 Figure 8c is a chromatogram for a reference sample

10

illustrated for comparison with the chromatograms of
Figures 8a and 8b;

5 Figure 9a is a chromatogram for a first test sample
prepared in accordance with a third example of a specific
method in accordance with the present invention;

10 Figure 9b is a chromatogram for a second test sample
prepared in accordance with a third example of a specific
method in accordance with the present invention;

15 Figure 9c is a chromatogram for a third test sample
prepared in accordance with a third example of a specific
method in accordance with the present invention;

Figure 9d is a chromatogram for a control sample
illustrated for comparison with the chromatograms of
Figures 9a, 9b, and 9c;

20 Figure 10a is a chromatogram for a first test sample
prepared in accordance with a fourth example of a
specific method in accordance with the present invention;

25 Figure 10b is a chromatogram for a second test sample
prepared in accordance with a fourth example of a

specific method in accordance with the present invention;

Figure 10c is a chromatogram for a control sample illustrated for comparison with the chromatograms of
5 Figures 10a and 10b;

Figure 11a is a chromatogram for a first test sample prepared in accordance with a fifth example of a specific method in accordance with the present invention;

10

Figure 11b is a chromatogram for a second test sample prepared in accordance with a fifth example of a specific method in accordance with the present invention;

15

Figure 11c is a chromatogram for a control sample illustrated for comparison with the chromatograms of Figures 11a and 11b;

20

Figure 12 is a schematic cross-sectional diagram of fermentation apparatus in accordance with a fourth specific embodiment of the invention;

Figure 13 is a side elevation of a fermentation vessel of the fermentation apparatus illustrated in Figure 12;

25

Figure 14 is a schematic cross-sectional diagram of the fermentation apparatus illustrated in Figure 12, in a mode of use operative to generate secondary metabolites;

5 Figure 15 is a schematic cross-sectional diagram of the fermentation apparatus in accordance with a fifth specific embodiment of the invention;

10 Figure 16 is a side elevation of a fermentation vessel of the fermentation apparatus illustrated in Figure 15;

Figure 17 is a schematic cross-sectional diagram of the fermentation apparatus illustrated in Figure 15 in a mode of use operative to generate secondary metabolites;

15 Figure 18 is a perspective view of a fermentation vessel of fermentation apparatus in accordance with a sixth specific embodiment of the invention;

20 Figure 19a is a spectrum generated by mass spectrometry of a sample generated in a sixth example in accordance with the invention;

25 Figure 19b is a view of an expanded portion of the spectrum illustrated in Figure 19a;

Figure 20 is a spectrum generated by mass spectrometry of a control sample corresponding with the sample generated in the sixth example;

5 Figure 21a is a spectrum generated by mass spectrometry of a further sample generated in the sixth example;

Figure 21b is a view of an exposed portion of the spectrum illustrated in Figure 21a;

10 Figure 22 is a spectrum generated by mass spectrometry of a control sample corresponding with the further sample of the sixth example;

15 Figure 23 is a spectrum generated by mass spectrometry of a sample generated in a seventh example in accordance with the invention; and

20 Figure 24 is a spectrum generated by mass spectrometry of a control sample corresponding with the sample whose spectrum is illustrated in Figure 23.

25 Figure 1 shows a fermentation apparatus 2 comprising a fermentation receptacle 10, which is generally cuboidal

in shape. The upper end of the receptacle 10 is open, and has a lid 12 fitted thereon. The receptacle 10 and the lid 12 are made of a plastics material capable of withstanding temperatures of up to 121°C in order to 5 allow for sterilisation thereof in the presence of steam. However, it will be appreciated that other materials, such as stainless steel or glass, would also be appropriate.

10 The lid 12 has a window 14 including a gas permeable foam insert 16, which allows the transfer of oxygen and carbon dioxide therethrough, as indicated by arrows in Figure 1.

15 The receptacle 10 contains an aqueous solution/suspension 18 of a combination of nutrients appropriate to the metabolism of a microorganism to be grown in the fermentation apparatus 2. Particular examples of nutrients and microorganisms will be described later.

20 Floating on the surface of the aqueous solution 18 is a raft 20. Accordingly, the volume of the aqueous solution/suspension 18 provided in the receptacle 10 is sufficient to allow flotation of the raft 20. The construction of the raft 20 is best illustrated with 25 reference to Figure 2. The raft 20 has a generally

square laminar body 22 with a square through aperture 24 located centrally therein. A flange 26 extends downwardly as illustrated in Figure 2 around the periphery of the square body 22.

5

As illustrated in Figure 1, the raft 20 is constructed of a material which renders it sufficiently buoyant as to float in the aqueous solution 18, such that the surface of the aqueous solution 18 reaches the level of the 10 square laminar body 22.

A fermentation vessel 28 is placed on the raft 20. The vessel 28, illustrated in Figure 3, consists of a generally square frame 30 supporting a membrane 32.

15

Figures 4 and 5 illustrate two alternative embodiments of the vessel 28 of different constructions. The first embodiment of the vessel 28 is illustrated in Figure 4. The membrane 32 of the vessel 28 is constructed of a 20 polypropylene sheet 34 with a pore size of 0.3 micrometers, welded to the frame 30. The polypropylene sheet 34 is treated with a silicone-polyether copolymer to make it water permeable. On the inside (upper) face of the polypropylene sheet 34 is placed a square melt 25 cast polypropylene fibre hydrophilised membrane 36, such

as a polypropylene membrane sold as a pre-filter by Millipore Corporation, 80 Ashby Road, Massachusetts, USA.

The solution/suspension held in the receptacle 10 soaks 5 through the polypropylene sheet 34 and is wicked by the membrane 36, so that any microorganism sample inoculated on to the membrane 36 has access to the solution/suspension 18. The soaking through of the solution/suspension can be by means of a pressure 10 gradient derived from the weight of the raft 20 and fermentation vessel 28 in combination.

The second specific embodiment is illustrated in Figure 5. The vessel 28' is constructed in the same manner as 15 the vessel 28 of the first specific embodiment, except that the membrane 32' thereof has a polypropylene fibre hydrophilised membrane 34', welded to the frame 30, in place of the polypropylene sheet 34.

20 In the case of the second specific embodiment, since both membranes 34', 36 are hydrophilic, solution/suspension 18 can soak into the membranes 34', 36 by wicking, brought about via capillary action.

25 A third specific embodiment of the invention is

illustrated in Figure 6. As far as the apparatus 2' of the third embodiment has features corresponding to features in the first and second embodiments, those features are provided with the same reference numerals.

5 The fermentation receptacle 10 of the apparatus 2' includes a drain outlet 40 which is closeable by means of a drain valve 42. In use, liquid contents of the fermentation receptacle 10 can be drained away through the drain outlet 40, which allows the fermentation receptacle 10 to be emptied without lifting and tipping thereof. Whereas the apparatus 2' of the third embodiment of the invention has been provided with a vessel 28 corresponding to the vessel 28 illustrated in Figure 4, it will be appreciated that the vessel could 10 also take the form of the vessel 28' illustrated in Figure 5.

20 Application of the above described first, second and third specific embodiments of the invention will now be described with reference to the following specific examples. The examples involve analysis of two fungi and three actinomycete bacteria.

25 The microorganisms need to be prepared in order to generate sufficient mycelial growth for investigation.

This requires the use of formulated growth media. The present invention allows the use of complex growth media.

5 Growth media suggested for promoting mycelial growth in fungi include FS and HC4, whose formulations are set out in Tables 1 and 2 below.

TABLE 1

10

FS	g/l
Sheftone -Z soy peptone	10
Malt extract, Oxoid L39	21
Glycerol	40
Junlon 110 (Honeywell & Stein)	1
Adjust to pH 6.3	

15

20

TABLE 2

25

HC4	g/l
Beet molasses, British Sugar	20
Glycerol	25
Casein NZ-Amine AS	7.5
K ₂ HPO ₄ (Anhydrous)	0.3
CaCO ₃	2.5
Tween 80	1 ml

30

Growth media suggested for promoting mycelial growth in actinomycetes include SV2 and MPGS, whose formulations are set out in Tables 3 and 4 below.

5

TABLE 3

SV2	g/l
D-Glucose	15
Glycerol	15
Sheftone -Z soy peptone	15
NaCl	3
CaCO ₃	1
Adjust to pH 7	

10

15

TABLE 4

MPGS	g/l
Beet molasses, British Sugar	20
Sheftone -Z soy peptone	5
D-Glucose	10
Sucrose	20
CaCO ₃	2.5

20

In order to induce secondary metabolism in a microorganism, a culture of the microorganism must be kept in an environment lacking (or having a reduced concentration in) one or more of the nutrients essential

30

to primary metabolism and growth. Therefore, the growth medium selected from the lists set out above must be replaced by a nutrient deficient medium. Several different nutrient deficient media require investigation 5 for each new microorganism, to ensure the identification of the most effective conditions for efficient secondary metabolism. For fungi, the replacement media listed in Table 5 are used in the following examples to investigate secondary metabolism using the apparatus of the specific 10 embodiment of the invention.

TABLE 5

Replacement media	
1.	Water
2.	Glucidex (Roquette Frères), 10 g/l
3.	Trehalose, 10 g/l
4.	Glycerol, 10 g/l
5.	Mannitol, 10 g/l

20

Water is used as a control, and the other four media contain a source of carbon. For actinomycetes, the replacement media set out in Table 6 are used in the 25 following examples to investigate secondary metabolism using the apparatus of the specific embodiment of the invention.

TABLE 6

Replacement media	
5	1. Water
	2. Glucidex, 10 g/l
	3. Glucidex, 10 g/l + Proline, 1.5 g/l (C:N is approximately 30:1)
	4. Glycerol, 10 g/l
	5. Glycerol, 10 g/l + Proline, 1.5 g/l (C:N is approximately 30:1)

10

15

Again, water is used as a control. The other four media contain either a source of carbon or a source of carbon and nitrogen. In the case of media 3 and 5 (Table 6), the carbon:nitrogen ratio (C:N) is set at 30:1 to establish conditions which particularly favour secondary metabolism.

20

Two specific procedures will now be described, for later use in the following examples.

Procedure 1 (Layer Inoculation)

25

The fermentation apparatus 2 is employed in a first procedure solely for secondary metabolism of a microorganism.

In this case, mycelial growth of the microorganism under

investigation is generated in a liquid culture, to serve as an inoculum later referred to as a layer inoculation. This is achieved in a plurality of 250 ml flasks each containing 50 ml growth medium. Each flask is 5 inoculated, in sterile conditions, from microorganism grown on agar slopes, and incubated, with agitation, at 25°C or 28°C, for 3 to 5 days.

A one litre flask, provided with automatic temperature 10 regulation and stirring devices, is filled with 300 ml of the same growth medium as used in the 250 ml flasks above. This is inoculated with 5% cell culture (about 15 ml) taken from the 250 ml flasks. The vessel is then stirred, using a 45 mm cross-shaped magnetic follower, at 15 300 rpm and incubated at 25°C for fungi and 28°C for actinomycetes. The culture is allowed to grow for up to 5 days, depending on the nature of the microorganism and its growth rate, in order to maintain the culture in growth phase, known as trophophase.

20

A fermentation apparatus 2 as described above is provided with a vessel 28' as illustrated in Figure 5. In order

to inoculate the apparatus 2, the vessel 28' is temporarily removed from the receptacle of the apparatus 2, and a 50 ml aliquot of the culture contained in the one litre flask is transferred directly to the membrane 5 surface 36. The supernatant is allowed to drain away before the vessel 28' is replaced in the receptacle 10, which contains 60 ml of a replacement medium as described above.

10 Procedure 2 (Plug Inoculation)

The apparatus 2 is used in a second exemplary method both for the preparation and growth of mycelium of a microorganism for inoculation and for subsequent nutrient secondary metabolism of the microorganism. Apparatus 2 15 in accordance with the first embodiment is provided as described above with reference to Figures 1 to 4 of the drawings. The receptacle 10 of the apparatus 2 is filled with a nutrient solution to a level sufficient to support flotation of the vessel (typically 60 - 70 ml).

20

For fungi, a plug of agar taken from the growing edge of a stock Petri dish culture of the microorganism under

investigation is deposited on the centre of the membrane 34, 36 of the vessel 28 on the raft 20.

For actinomycetes, inoculation is carried out by placing 5 a spore/mycelial suspension onto the membrane of the vessel 30, the suspension having been prepared from a stock culture of the organism maintained, for instance, on a slope.

10 The inoculated vessel 30 is retained in the fermentation receptacle 10 for fifteen days, before it is transferred aseptically to a new fermentation receptacle 10 containing 60 ml of a replacement medium as identified above.

15

Secondary Metabolism

After placement in contact with a replacement medium, fungal cultures are incubated at 25°C, and actinomycete cultures at 28°C, for up to 2 weeks to achieve maximum 20 productivity of secondary metabolites.

Notwithstanding the existence of water as a control

replacement medium, control samples are also advisedly established in investigations, in which sample no transfer to a replacement medium takes place. In the case of plug inoculation, a control is established which 5 comprises a fermentation apparatus 2 inoculated with a plug of mycelial growth, which is then left in the same growth medium for the duration of the trials. In the case of layer inoculation, a control is established by transferring mycelial biomass to a vessel 28 and allowing 10 it to drain through. The vessel 28 is then placed in a fermentation receptacle 10 containing the same growth medium as was used to generate the layer inoculation, again for the duration of the trials.

15 Metabolite Isolation

Secondary metabolite can be produced in the cells of the microorganism under test, in the fermentation broth in which the microorganism resides, or in both. Therefore, samples of both mycelium and filtrate are taken. The 20 mycelium sample is extracted with 10 ml methanol for a minimum of twelve hours, following which the extract is subjected to chromatographic analysis. The broth sample

is diluted in suitable HPLC mobile phase, following which it is also subjected to chromatographic analysis. Suitable HPLC conditions will be described for each example outlined below.

5

Each example outlined below demonstrates the use of the fermentation apparatus of the present invention in the execution of a number of different tasks. The examples demonstrate investigations into the effectiveness of the 10 fermentation apparatus illustrated in Figure 1, and the method of transferring a microorganism into conditions supporting secondary metabolism, to generate secondary metabolite from five microorganisms treated in a variety of different ways. The five microorganisms investigated 15 in the examples are *Phoma* sp. F16006 and *Trichoderma longibraciatum* 5602E, which are fungi, and *Amycolatopsis orientalis* C2726, *Nocardiopsis* sp. 5997E, and *Streptomyces citricolor* C2778 which are actinomycetes.

20 Each of the fungi are to be treated in the same manner, likewise the actinomycetes. The microorganisms should be tested under all combinations of available conditions.

In respect of each fungus, twenty fermentation apparatus 2 need to be prepared. A first group of five fermentation apparatus 2 are prepared with a layer inoculum from a liquid culture generated in FS growth medium and a second group of five with a layer inoculum from liquid culture prepared in HC4 growth medium, in accordance with procedure 1. A third group of five apparatus 2 are prepared with plug inoculated cultures grown on FS medium and a fourth group of five apparatus 2 with plug inoculated cultures grown on HC4 growth medium, in accordance with procedure 2.

Each receptacle 10 of the five apparatus 2 in each group is filled with a respective one of the five replacement media set out in Table 5. The twenty fermentation apparatus 2 so inoculated are maintained for ten days before harvest.

Four control apparatus 2 are also arranged, two of which 20 are layer inoculated from four day old liquid cultures (one from each of the two available growth media), and the other two of which are inoculated using the plug

inoculation technique (from the two available growth media). The fermenting receptacles 10 are filled with corresponding growth media, not replacement media. The apparatus are left for fifteen days before harvest for 5 layer inoculated cultures, and twenty five days before harvest for plug inoculated cultures.

Each of the actinomycetes are to be treated in the same general manner, but with some differences in the specific 10 procedures employed. Again, twenty test apparatus 2 and four control apparatus 2 are assembled, since two growth media SV2, MPGS and five replacement media (Table 6) are available. However, the duration of each stage is in some cases different. In the case of Procedure 1 for 15 actinomycetes, liquid culture for layer inoculation is grown for five days rather than four as per fungi. Incubation after transfer to replacement medium is conducted for ten days rather than the eleven day period set down for fungi. Again, layer inoculum control 20 cultures are grown for 5 days before transfer to apparatus 2 containing growth media.

After completion of the relevant incubation period, investigations are put in place to measure the production of metabolite in cell extract and broth extract. In order to measure concentrations of secondary metabolite, 5 the extract under investigation is subjected to HPLC under suitable conditions.

The operating parameters and mobile phase formulations for all examples, except Example B, are set out in Table 10 7. Chemical standards are used to identify chromatographic peaks corresponding to the secondary metabolites produced by the test organisms.

TABLE 7

Time (Min)	% Mobile Phase B	Flow (ml/min)
0	0	1
20	100	1
30	100	1
32	0	1
35	0	1

20 **Mobile Phase A:** 5 g/litre sodium lauryl sulphate + 10 ml/litre 0.1M $\text{NH}_4\text{H}_2\text{PO}_4$, pH 2.5.

25 **Mobile Phase B:** 75% CH_3CN + 5 g/litre sodium lauryl sulphate + 10 ml/litre 0.1M $\text{NH}_4\text{H}_2\text{PO}_4$, pH 2.5.

Column: Spherisorb 15 cm C5 5 micron.

The conditions for Example B has formulation set out in Table 8.

TABLE 8

5

Time (Min)	% Mobile Phase B	Flow (ml/min)
0	0	1
1	0	1
30	100	1
35	100	1
36	0	1
40	0	1

Mobile Phase A: 0.1% TFA.

15

Mobile Phase B: 75% CH₃CN + 0.1% TFA.

Column: Hypersil 15 cm C18 3 micron.

20

Finally, standard shaken cultures in accordance with known techniques are also carried out as a comparison of general bioreactor performance. The growth media for these cultures are FS (formulation previously described), SM37, BFMS and K252/P1. The formulations for the latter three media are:

SM37	g/l	BFMS	g/l	K252/P1	g/l
Lactose	25	Arkasoy	10	Glucose	5
KH_2PO_4	4	Glucose	18	Soluble starch	30
CaCO_3	10	CaCO_3	0.2	Arkasoy	20
5 Pharmamedia	20	$\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$	0.001	Yeast extract	5
pH to 6.5		Na_2SO_4	1	Corn steep liquor	5
		Molasses	18	CaCO_3	3
		Sucrose	18	pH to 7.2	

10

The results of the HPLC tests for selected samples produced by the following examples are illustrated as chromatograms in Figures 7a and 7b, Figures 8a, 8b and 8c, Figures 9a, 9b, 9c and 9d, Figures 10a, 10b and 10c and Figures 11a, 11b and 11c. A chromatogram is a graph of Absorbance (measured in milli Absorbance Units) against retention time (measured in Minutes). Each chromatogram is marked with an arrow pointing at a peak which represents the expected secondary metabolite for that particular sample.

15

20

25

Example A - Phoma sp. F16006

This fungus produces compound GR 195359. The results of the procedures applied to the microorganism are set out in Table 9.

TABLE 9

TEST								
Ref.	Organism	Metabolite	Inoculum Type	Growth Medium	Replacement Medium	Extract Type	Conc. (mg/l)	
5	A1	Phoma sp F16006	GR 195359	Layer	FS	water	cell	0
	A2	Phoma sp F16006	GR 195359	Layer	FS	glucidex	cell	0
	A3	Phoma sp F16006	GR 195359	Layer	FS	trehalose	cell	0
	A4	Phoma sp F16006	GR 195359	Layer	FS	glycerol	cell	0
	A5	Phoma sp F16006	GR 195359	Layer	FS	mannitol	cell	0
	A6	Phoma sp F16006	GR 195359	Layer	FS	water	broth	0
	A7	Phoma sp F16006	GR 195359	Layer	FS	glucidex	broth	0
10	A8	Phoma sp F16006	GR 195359	Layer	FS	trehalose	broth	0
	A9	Phoma sp F16006	GR 195359	Layer	FS	glycerol	broth	0
	A10	Phoma sp F16006	GR 195359	Layer	FS	mannitol	broth	0
	A11	Phoma sp F16006	GR 195359	Layer	HC4	water	cell	0
	A12	Phoma sp F16006	GR 195359	Layer	HC4	glucidex	cell	0
	A13	Phoma sp F16006	GR 195359	Layer	HC4	trehalose	cell	0
	A14	Phoma sp F16006	GR 195359	Layer	HC4	glycerol	cell	0
15	A15	Phoma sp F16006	GR 195359	Layer	HC4	mannitol	cell	246
	A16	Phoma sp F16006	GR 195359	Layer	HC4	water	broth	0
	A17	Phoma sp F16006	GR 195359	Layer	HC4	glucidex	broth	0
	A18	Phoma sp F16006	GR 195359	Layer	HC4	trehalose	broth	0
	A19	Phoma sp F16006	GR 195359	Layer	HC4	glycerol	broth	0
	A20	Phoma sp F16006	GR 195359	Layer	HC4	mannitol	broth	0
	A21	Phoma sp F16006	GR 195359	Plug	FS	water	cell	134
20	A22	Phoma sp F16006	GR 195359	Plug	FS	glucidex	cell	529
	A23	Phoma sp F16006	GR 195359	Plug	FS	trehalose	cell	525
	A24	Phoma sp F16006	GR 195359	Plug	FS	glycerol	cell	519
	A25	Phoma sp F16006	GR 195359	Plug	FS	mannitol	cell	876
	A26	Phoma sp F16006	GR 195359	Plug	FS	water	broth	0
	A27	Phoma sp F16006	GR 195359	Plug	FS	glucidex	broth	0
	A28	Phoma sp F16006	GR 195359	Plug	FS	trehalose	broth	0
25	A29	Phoma sp F16006	GR 195359	Plug	FS	glycerol	broth	0
	A30	Phoma sp F16006	GR 195359	Plug	FS	mannitol	broth	0
	A31	Phoma sp F16006	GR 195359	Plug	HC4	water	cell	0
	A32	Phoma sp F16006	GR 195359	Plug	HC4	glucidex	cell	0
	A33	Phoma sp F16006	GR 195359	Plug	HC4	trehalose	cell	0
	A34	Phoma sp F16006	GR 195359	Plug	HC4	glycerol	cell	0
	A35	Phoma sp F16006	GR 195359	Plug	HC4	mannitol	cell	85
30	A36	Phoma sp F16006	GR 195359	Plug	HC4	water	broth	0
	A37	Phoma sp F16006	GR 195359	Plug	HC4	glucidex	broth	0

TEST								
A38	Phoma sp F16006	GR 195359	Plug	HC4	trehalose	broth	0	
A39	Phoma sp F16006	GR 195359	Plug	HC4	glycerol	broth	0	
A40	Phoma sp F16006	GR 195359	Plug	HC4	mannitol	broth	0	
CONTROL								
5	A41	Phoma sp F16006	GR 195359	Layer	FS	FS	cell	0
	A42	Phoma sp F16006	GR 195359	Layer	FS	FS	broth	0
	A43	Phoma sp F16006	GR 195359	Layer	HC4	HC4	cell	0
	A44	Phoma sp F16006	GR 195359	Layer	HC4	HC4	broth	0
10	A45	Phoma sp F16006	GR 195359	Plug	FS	FS	cell	608
	A46	Phoma sp F16006	GR 195359	Plug	FS	FS	broth	0
	A47	Phoma sp F16006	GR 195359	Plug	HC4	HC4	cell	0
	A48	Phoma sp F16006	GR 195359	Plug	HC4	HC4	broth	0
	A49	Phoma sp F16006	GR 195359	Shaken	SM37		culture	109

15

In the example, GR 195359 is produced, with two exceptions, on FS medium in cultures inoculated by the plug method. GR 195359 is extracted only from the cell material. The nature of the replacement medium affects the amount of GR 195359 produced by the organism, as demonstrated by test samples A21-A25. In particular, mannitol produces the highest titre of GR 195359 and is able to stimulate production in layer and plug replacement cultures grown on HC4 medium, as shown in samples A15 and A35 respectively. Mannitol stimulates the production of GR 195359 significantly beyond the level achievable in the corresponding control A45 arranged without transfer to replacement medium.

HPLC chromatograms reveal that in cell extracts A21 - A25 in respect of which the microorganism has been transferred to replacement medium, the size of the GR 195359 peak relative to the other component peaks is 5 significantly greater than in control samples. This indicates that there is a higher proportion of GR 195359 in cell extracts of replacement cultures. This is illustrated in Figure 7a, which illustrates sample A25, in comparison with Figure 7b, which shows its control 10 A45.

Although the titres are not directly comparable, the concentrations of GR 195359 in the described cell extracts are superior to levels in whole culture extracts 15 of *Phoma sp.* F16006 grown in traditional shake flasks on an optimised medium.

Example B - *Trichoderma longibraciatum* 5602E

This fungus produces bisvertinolone. The results of the procedures described above applied to the microorganism 5 are set out in Table 10.

TABLE 10

TEST							
Ref.	Organism	Metabolite	Inoculum Type	Growth Medium	Replacement Medium	Extract Type	Conc (mg/l)
B1	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	FS	water	cell	0
B2	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	FS	glucidex	cell	0
B3	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	FS	trehalose	cell	43.6
B4	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	FS	glycerol	cell	0
B5	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	FS	mannitol	cell	0
B6	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	FS	water	broth	406.3
B7	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	FS	glucidex	broth	115.6
B8	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	FS	trehalose	broth	196.0
B9	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	FS	glycerol	broth	304.0
B10	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	FS	mannitol	broth	168.3
B11	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	HC4	water	cell	0
B12	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	HC4	glucidex	cell	0
B13	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	HC4	trehalose	cell	322.6
B14	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	HC4	glycerol	cell	456.1
B15	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	HC4	mannitol	cell	240.2
B16	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	HC4	water	broth	798.3
B17	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	HC4	glucidex	broth	1448.0
B18	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	HC4	trehalose	broth	2505.0
B19	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	HC4	glycerol	broth	3407.9
B20	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	HC4	mannitol	broth	2328.1
B21	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	FS	water	cell	0
B22	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	FS	glucidex	cell	1669.9
B23	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	FS	trehalose	cell	1325.2
B24	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	FS	glycerol	cell	901.7
B25	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	FS	mannitol	cell	1333.6
B26	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	FS	water	broth	1214.6
B27	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	FS	glucidex	broth	1439.8
B28	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	FS	trehalose	broth	617.6
B29	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	FS	glycerol	broth	802.2
B30	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	FS	mannitol	broth	1227.8
B31	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	HC4	water	cell	432.9
B32	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	HC4	glucidex	cell	1046.2
B33	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	HC4	trehalose	cell	219.6
B34	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	HC4	glycerol	cell	276.6
B35	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	HC4	mannitol	cell	378.0
B36	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	HC4	water	broth	798.4

TEST							
Ref.	Organism	Metabolite	Inoculum Type	Growth Medium	Replacement Medium	Extract Type	Conc. (mg/l)
B37	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	HC4	glucidex	broth	2821.6
B38	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	HC4	trehalose	broth	1510.8
B39	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	HC4	glycerol	broth	3263.7
B40	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	HC4	mannitol	broth	2078.7

CONTROL							
Ref.	Organism	Metabolite	Layer	FS	FS	cell	892.9
B41	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	FS	FS	broth	344.7
B42	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	FS	HC4	cell	5256.5
B43	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	HC4	HC4	broth	2451.2
B44	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Layer	HC4	HC4	cell	659.5
B45	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	FS	FS	broth	660.5
B46	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	FS	FS	cell	1470.4
B47	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	HC4	HC4	broth	2186.5
B48	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Plug	HC4	HC4	culture	6400
B49	<i>T. longibrachiatum</i> 5602E	bisvertinolone	Shaken	FS			

15

From the results, it can be observed that the fungus produces its secondary metabolite under most circumstances, generally as effectively in the apparatus of the present invention as in traditional shaken cultures.

25 The apparatus allows for secretion of secondary metabolites into the highly defined replacement medium and the generation of less complex mixtures of wholly fungal origin. This is exemplified in Figure 8a by the HPLC chromatogram for broth sample B19 which has a

flatter baseline and shows better peak separation than the corresponding cell extract B14 illustrated in Figure 8c. Where the replacement medium is water as in sample B16, the chromatogram is simplified even further (Figure 5 8b).

Example C - *Amycolatopsis orientalis* C2726

This actinomycete bacterium produces vancomycin. The results of the procedures applied to the microorganism 10 are set out in Table 11.

TABLE 11

TEST							
Ref.	Organism	Metabolite	Inoculum Type	Growth Medium	Replacement Medium	Extract Type	Conc. (mg/l)
C1	A orientalis C2726	vancomycin	Layer	SV2	water	cell	0
C2	A orientalis C2726	vancomycin	Layer	SV2	glucidex	cell	0
C3	A orientalis C2726	vancomycin	Layer	SV2	glucidex + proline	cell	0
C4	A orientalis C2726	vancomycin	Layer	SV2	glycerol	cell	0
C5	A orientalis C2726	vancomycin	Layer	SV2	glycerol + proline	cell	0
C6	A orientalis C2726	vancomycin	Layer	SV2	water	broth	52.1
C7	A orientalis C2726	vancomycin	Layer	SV2	glucidex	broth	79.3
C8	A orientalis C2726	vancomycin	Layer	SV2	glucidex + proline	broth	49.8
C9	A orientalis C2726	vancomycin	Layer	SV2	glycerol	broth	76.9
C10	A orientalis C2726	vancomycin	Layer	SV2	glycerol + proline	broth	58.6
C11	A orientalis C2726	vancomycin	Layer	MPGS	water	cell	0
C12	A orientalis C2726	vancomycin	Layer	MPGS	glucidex	cell	0
C13	A orientalis C2726	vancomycin	Layer	MPGS	glucidex + proline	cell	0
C14	A orientalis C2726	vancomycin	Layer	MPGS	glycerol	cell	0

TEST								
C15	A orientalis C2726	vancomycin	Layer	MPGS	glycerol + proline	cell	0	
C16	A orientalis C2726	vancomycin	Layer	MPGS	water	broth	20 3	
C17	A orientalis C2726	vancomycin	Layer	MPGS	glucidex	broth	95 2	
C18	A orientalis C2726	vancomycin	Layer	MPGS	glucidex + proline	broth	120 9	
5	C19	A orientalis C2726	vancomycin	Layer	MPGS	glycerol	broth	142 3
C20	A orientalis C2726	vancomycin	Layer	MPGS	glycerol + proline	broth	207 9	
10	C21	A orientalis C2726	vancomycin	Plug	SV2	water	cell	0
C22	A orientalis C2726	vancomycin	Plug	SV2	glucidex	cell	0	
C23	A orientalis C2726	vancomycin	Plug	SV2	glucidex + proline	cell	14 6	
15	C24	A orientalis C2726	vancomycin	Plug	SV2	glycerol	cell	6 6
C25	A orientalis C2726	vancomycin	Plug	SV2	glycerol + proline	cell	36 9	
C26	A orientalis C2726	vancomycin	Plug	SV2	water	broth	15 1	
C27	A orientalis C2726	vancomycin	Plug	SV2	glucidex	broth	9 1	
20	C28	A orientalis C2726	vancomycin	Plug	SV2	glucidex + proline	broth	73 5
C29	A orientalis C2726	vancomycin	Plug	SV2	glycerol	broth	110 8	
C30	A orientalis C2726	vancomycin	Plug	SV2	glycerol + proline	broth	86 9	
C31	A orientalis C2726	vancomycin	Plug	MPGS	water	cell	0 0	
C32	A orientalis C2726	vancomycin	Plug	MPGS	glucidex	cell	0 0	
C33	A orientalis C2726	vancomycin	Plug	MPGS	glucidex + proline	cell	8 2	
25	C34	A orientalis C2726	vancomycin	Plug	MPGS	glycerol	cell	6 8
C35	A orientalis C2726	vancomycin	Plug	MPGS	glycerol + proline	cell	15 1	
C36	A orientalis C2726	vancomycin	Plug	MPGS	water	broth	0 0	
C37	A orientalis C2726	vancomycin	Plug	MPGS	glucidex	broth	17 4	
C38	A orientalis C2726	vancomycin	Plug	MPGS	glucidex + proline	broth	43 9	
30	C39	A orientalis C2726	vancomycin	Plug	MPGS	glycerol	broth	51 1
C40	A orientalis C2726	vancomycin	Plug	MPGS	glycerol + proline	broth	36 1	
CONTROL								
C41	A orientalis C2726	vancomycin	Layer	SV2	SV2	cell	29 3	
C42	A orientalis C2726	vancomycin	Layer	SV2	SV2	broth	0	
C43	A orientalis C2726	vancomycin	Layer	MPGS	MPGS	cell	0	
C44	A orientalis C2726	vancomycin	Layer	MPGS	MPGS	broth	0	
C45	A orientalis C2726	vancomycin	Plug	SV2	SV2	cell	0	
C46	A orientalis C2726	vancomycin	Plug	SV2	SV2	broth	0	
35	C47	A orientalis C2726	vancomycin	Plug	MPGS	MPGS	cell	0
C48	A orientalis C2726	vancomycin	Plug	MPGS	MPGS	broth	0	
C49	A orientalis C2726	vancomycin	Shaken	BFMS		culture	307	

40 The results show that the apparatus supports the

production of vancomycin by this actinomycete, specifically in the broth of layer cultures and more generally over plug cultures. The generally poorer performance of water as a replacement medium indicates 5 the importance of a carbon source or a carbon and nitrogen source in a specified ratio, to enhance the production of vancomycin.

In the eight control cultures C41 to C48 performed in 10 apparatus as described above, vancomycin is only detectable in one culture C41. These results indicate that a nutrient replacement procedure to media containing a carbon or carbon and nitrogen source is essential to consistently produce vancomycin from the primary growth 15 media SV2 and MPGS.

HPLC chromatograms for broths exemplified in Figures 9a, 9b and 9c, for samples C16, C17 and C19 respectively, show flatter baselines, fewer components and better peak 20 separation than the control cell extract exemplified by sample C41, whose HPLC chromatogram is illustrated in Figure 9d. In addition, comparison of the HPLC

chromatograms for individual spectra exemplified by samples C16, C17 and C19 show differences in vancomycin titre and subtle differences in the overall pattern of peaks.

5

Example D - *Nocardiopsis* sp. 5997E

This actinomycete bacterium produces K252a. The results of the procedures applied to the microorganism are set out in Table 12.

10

TABLE 12

TEST							
Ref.	Organism	Metabolite	Inoculum Type	Growth Medium	Replacement Medium	Extract Type	Conc. (mg/l)
D1	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	SV2	water	cell	15
D2	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	SV2	glucidex	cell	0
D3	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	SV2	glucidex + proline	cell	13
D4	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	SV2	glycerol	cell	46
D5	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	SV2	glycerol + proline	cell	32
D6	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	SV2	water	broth	0
D7	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	SV2	glucidex	broth	0
D8	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	SV2	glucidex + proline	broth	0
D9	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	SV2	glycerol	broth	0
D10	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	SV2	glycerol + proline	broth	0
D11	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	MPGS	water	cell	1962
D12	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	MPGS	glucidex	cell	1991
D13	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	MPGS	glucidex + proline	cell	2342
D14	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	MPGS	glycerol	cell	2275
D15	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	MPGS	glycerol + proline	cell	2435
D16	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	MPGS	water	broth	0
D17	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	MPGS	glucidex	broth	0
D18	<i>Nocardiopsis</i> sp 5997E	K252a	Layer	MPGS	glucidex + proline	broth	0

TEST							
D19	Nocardiopsis sp 5997E	K252a	Layer	MPGS	glycerol	broth	0
D20	Nocardiopsis sp 5997E	K252a	Layer	MPGS	glycerol + proline	broth	0
D21	Nocardiopsis sp 5997E	K252a	Plug	SV2	water	cell	0
D22	Nocardiopsis sp 5997E	K252a	Plug	SV2	glucidex	cell	0
D23	Nocardiopsis sp 5997E	K252a	Plug	SV2	glucidex + proline	cell	0
D24	Nocardiopsis sp 5997E	K252a	Plug	SV2	glycerol	cell	0
D25	Nocardiopsis sp 5997E	K252a	Plug	SV2	glycerol + proline	cell	0
D26	Nocardiopsis sp 5997E	K252a	Plug	SV2	water	broth	0
D27	Nocardiopsis sp 5997E	K252a	Plug	SV2	glucidex	broth	0
D28	Nocardiopsis sp 5997E	K252a	Plug	SV2	glucidex + proline	broth	0
D29	Nocardiopsis sp 5997E	K252a	Plug	SV2	glycerol	broth	0
D30	Nocardiopsis sp 5997E	K252a	Plug	SV2	glycerol + proline	broth	0
D31	Nocardiopsis sp 5997E	K252a	Plug	MPGS	water	cell	0
D32	Nocardiopsis sp 5997E	K252a	Plug	MPGS	glucidex	cell	0
D33	Nocardiopsis sp 5997E	K252a	Plug	MPGS	glucidex + proline	cell	0
D34	Nocardiopsis sp 5997E	K252a	Plug	MPGS	glycerol	cell	0
D35	Nocardiopsis sp 5997E	K252a	Plug	MPGS	glycerol + proline	cell	0
D36	Nocardiopsis sp 5997E	K252a	Plug	MPGS	water	broth	0
D37	Nocardiopsis sp 5997E	K252a	Plug	MPGS	glucidex	broth	0
D38	Nocardiopsis sp 5997E	K252a	Plug	MPGS	glucidex + proline	broth	0
D39	Nocardiopsis sp 5997E	K252a	Plug	MPGS	glycerol	broth	0
D40	Nocardiopsis sp 5997E	K252a	Plug	MPGS	glycerol + proline	broth	0
CONTROL							
D41	Nocardiopsis sp 5997E	K252a	Layer	SV2	SV2	cell	0
D42	Nocardiopsis sp 5997E	K252a	Layer	SV2	SV2	broth	0
D43	Nocardiopsis sp 5997E	K252a	Layer	MPGS	MPGS	cell	2284
D44	Nocardiopsis sp 5997E	K252a	Layer	MPGS	MPGS	broth	644
D45	Nocardiopsis sp 5997E	K252a	Plug	SV2	SV2	cell	0
D46	Nocardiopsis sp 5997E	K252a	Plug	SV2	SV2	broth	0
D47	Nocardiopsis sp 5997E	K252a	Plug	MPGS	MPGS	cell	0
D48	Nocardiopsis sp 5997E	K252a	Plug	MPGS	MPGS	broth	0
D49	Nocardiopsis sp 5997E	K252a	Shaken	K252/P1		culture	2108

35

The results show that metabolite K252a is most effectively produced in cell extracts of layer cultures transferred to replacement medium following growth in

MPGS medium. Titres of K252a in these culture samples D11 to D15 are not significantly different from the control culture D43. However, comparison of HPLC spectra for samples D11 and D15, as illustrated in Figures 10a 5 and 10b, show that cell extracts for those samples contain fewer, well defined peaks than shown in the HPLC chromatogram for control sample D43 (Figure 10c), indicating the existence of simpler solutions.

10 Again this example shows that although the titres are low, the described procedure induces production of K252a in SV2 medium when none is produced under control conditions. This demonstrates that the apparatus can be used to produce secondary metabolites through the use of 15 only a limited number of media, whereas up to ten media would previously have been required.

Example E - *Streptomyces citricolor* C2778

This actinomycete bacterium produces the compound 20 aristeromycin. The results of the procedures applied to the microorganism are set out in Table 13.

TABLE 13

TEST								
Ref:	Organism	Metabolite	Inoculum Type	Growth Medium	Replacement Medium	Extract Type	Conc. (mg/l)	
5	E1	S. citricolor C2778	aristeromycin	Layer	SV2	water	cell	5
	E2	S. citricolor C2778	aristeromycin	Layer	SV2	glucidex	cell	3
	E3	S. citricolor C2778	aristeromycin	Layer	SV2	glucidex + proline	cell	9
	E4	S. citricolor C2778	aristeromycin	Layer	SV2	glycerol	cell	3
	E5	S. citricolor C2778	ansteromycin	Layer	SV2	glycerol + proline	cell	10
	E6	S. citricolor C2778	ansteromycin	Layer	SV2	water	broth	22
	E7	S. citricolor C2778	ansteromycin	Layer	SV2	glucidex	broth	20
	E8	S. citricolor C2778	ansteromycin	Layer	SV2	glucidex + proline	broth	28
	E9	S. citricolor C2778	ansteromycin	Layer	SV2	glycerol	broth	16
	E10	S. citricolor C2778	ansteromycin	Layer	SV2	glycerol + proline	broth	41
	E11	S. citricolor C2778	aristeromycin	Layer	MPGS	water	cell	3
	E12	S. citricolor C2778	aristeromycin	Layer	MPGS	glucidex	cell	9
	E13	S. citricolor C2778	aristeromycin	Layer	MPGS	glucidex + proline	cell	16
	E14	S. citricolor C2778	ansteromycin	Layer	MPGS	glycerol	cell	12
	E15	S. citricolor C2778	ansteromycin	Layer	MPGS	glycerol + proline	cell	5
	E16	S. citricolor C2778	ansteromycin	Layer	MPGS	water	broth	23
	E17	S. citricolor C2778	ansteromycin	Layer	MPGS	glucidex	broth	36
	E18	S. citricolor C2778	ansteromycin	Layer	MPGS	glucidex + proline	broth	48
	E19	S. citricolor C2778	aristeromycin	Layer	MPGS	glycerol	broth	68
	E20	S. citricolor C2778	ansteromycin	Layer	MPGS	glycerol + proline	broth	37
	E21	S. citricolor C2778	ansteromycin	Plug	SV2	water	cell	0
	E22	S. citricolor C2778	ansteromycin	Plug	SV2	glucidex	cell	0
	E23	S. citricolor C2778	aristeromycin	Plug	SV2	glucidex + proline	cell	0
	E24	S. citricolor C2778	aristeromycin	Plug	SV2	glycerol	cell	0
	E25	S. citricolor C2778	aristeromycin	Plug	SV2	glycerol + proline	cell	0
	E26	S. citricolor C2778	aristeromycin	Plug	SV2	water	broth	0
	E27	S. citricolor C2778	ansteromycin	Plug	SV2	glucidex	broth	0
	E28	S. citricolor C2778	ansteromycin	Plug	SV2	glucidex + proline	broth	0
	E29	S. citricolor C2778	aristeromycin	Plug	SV2	glycerol	broth	0
	E30	S. citricolor C2778	ansteromycin	Plug	SV2	glycerol + proline	broth	0
	E31	S. citricolor C2778	ansteromycin	Plug	MPGS	water	cell	0
	E32	S. citricolor C2778	ansteromycin	Plug	MPGS	glucidex	cell	0
	E33	S. citricolor C2778	aristeromycin	Plug	MPGS	glucidex + proline	cell	0
	E34	S. citricolor C2778	aristeromycin	Plug	MPGS	glycerol	cell	6
	E35	S. citricolor C2778	aristeromycin	Plug	MPGS	glycerol + proline	cell	0
	E36	S. citricolor C2778	aristeromycin	Plug	MPGS	water	broth	4
	E37	S. citricolor C2778	aristeromycin	Plug	MPGS	glucidex	broth	2

TEST							
E38	S. citricolor C2778	aristeromycin	Plug	MPGS	glucidex + proline	broth	0
E39	S. citricolor C2778	aristeromycin	Plug	MPGS	glycerol	broth	16
E40	S. citricolor C2778	aristeromycin	Plug	MPGS	glycerol + proline	broth	0
CONTROL							
5	E41	S. citricolor C2778	aristeromycin	Layer	SV2	SV2	cell
	E42	S. citricolor C2778	aristeromycin	Layer	SV2	SV2	broth
	E43	S. citricolor C2778	aristeromycin	Layer	MPGS	MPGS	cell
	E44	S. citricolor C2778	aristeromycin	Layer	MPGS	MPGS	broth
10	E45	S. citricolor C2778	aristeromycin	Plug	SV2	SV2	cell
	E46	S. citricolor C2778	aristeromycin	Plug	SV2	SV2	broth
	E47	S. citricolor C2778	aristeromycin	Plug	MPGS	MPGS	cell
	E48	S. citricolor C2778	aristeromycin	Plug	MPGS	MPGS	broth
	E49	S. citricolor C2778	aristeromycin	Shaken	GAM6.6		culture

15

The results show that the apparatus supports the production of aristeromycin by this actinomycete, specifically in layer cultures and more generally over plug cultures. In layer cultures and for both SV2 and MPGS media significantly higher levels of aristeromycin are found in the broth samples from cultures produced in accordance with the invention. The titres of aristeromycin in those cultures are comparable to the controls (no transfer to replacement medium) but HPLC chromatograms reveal that broth samples in those cultures are much simpler chemically than samples from the controls and contain a very much higher proportion of aristeromycin relative to other sample components. This

is illustrated in Figures 11a and 11b with reference to E16 and E19, with their corresponding control sample E44 illustrated in Figure 11c.

5 The examples set out above demonstrate that metabolite titres achieved in the apparatus of the specific embodiments of the invention approach those which are achievable in a traditional liquid shaken culture system which would use an optimised medium for a specific
10 microorganism. The present invention as exemplified by the preceding procedures makes use of generalised growth media and replacement media which are nutrient deficient, rather than specialised media. By using generalised media, large scale trials with a plurality of different
15 microorganisms can be made much more cost effective.

In all the examples where the secondary metabolite is secreted into the nutrient deficient medium, the proportion of metabolite relative to the other
20 components, as indicated by HPLC, is very significantly enhanced over controls. This enables the sample to be concentrated by solvent evaporation to further increase

the concentration of the specific metabolite without raising the concentration of non-specific components to a level where they would cause interference if the sample is tested in a biological assay. This equally applies to 5 analysis by Matrix Assisted Laser Desorption Ionisation Time of Flight (MALDI-TOF) mass spectrometry (and other analytical systems) where the measurement of a desired analyte can be significantly enhanced by the removal of potentially interfering substances.

10

The enhanced resolution of peaks in HPLC chromatograms of samples as shown in Figures 7a, 8a and 8b, 9a, 9b and 9c, 10a and 10b, and 11a and 11b in comparison with Figures 7, 8c, 9d, 10c and 11c respectively demonstrates that the 15 present method as exemplified herein permits easier separation of desired secondary metabolites from other chemicals than possible with previous fermentation apparatus and methods.

20 The invention allows for separation of the microorganism under investigation from the growth medium in which mycelial biomass is generated, in such a manner that

secondary metabolism of the microorganism can be carefully controlled. Secondary metabolism can be carried out in a medium which is designed to promote production of a particular metabolite. In that way, 5 specific components may be included in the replacement medium, as an inducer or precursor to the mechanism by which metabolites are produced. For example, test sample A25 demonstrates that mannitol has a stimulatory effect on the production of GR 195359 as a secondary metabolite 10 of *Phoma sp.* F16006.

Further specific embodiments of the apparatus in accordance with the present invention will now be described with reference to Figures 12 to 18 of the 15 accompanying drawings. It will be understood that the apparatus described below makes use of the same principles as the apparatus previously described, and so it can be used to generate secondary metabolites in the same manner. However, the apparatus described below has 20 specific advantages which will become apparent from the following description.

With reference to Figure 12, fermentation apparatus 100 in accordance with a fourth embodiment of the invention comprises a fermentation receptacle 110 of generally cylindrical shape. A lid 112 is threadingly engaged to 5 one end thereof. The lid 112 has a throughbore 114, from which a peripheral flange 113 extends into the receptacle 110. A fermentation vessel 128 of generally cylindrical shape has an end taper-fitted to the flange 113. The opposite end of the vessel 128 is terminated at an acute 10 angle to the longitudinal axis of the vessel 128, thereby forming a surface of elliptical shape. That end of the vessel 128 has two membranes 134, 136 formed thereacross, each being of 0.6 micrometers pore size hydrophilised melt cast polypropylene. The outer membrane 134 is fixed 15 to the body of the vessel 128, and the inner membrane 136 is laid across the outer membrane 134. In that way, the inner membrane 136 can be removed from the vessel 128. A polystyrene foam filter 116 is placed in the bore 114.

20 By fitting the vessel 128 to the lid 112, the vessel 128 can be transferred into and out of the receptacle easily while maintaining aseptic conditions.

Figure 13 illustrates the fermentation vessel 128 in more detail. This shows the elliptical shape of the bottom end of the vessel 128, comprising the membrane 134.

5 The apparatus illustrated in Figure 12 can be used to generate mycelial biomass, by including a quantity of a growth medium 118 in the receptacle 110. The tip of the vessel 128 dips into the growth medium, and the two membranes 134, 136 act as a wick, growth medium being 10 drawn up into the membranes 134, 136 by capillary action.

The inner membrane 136 is inoculated with a microorganism, which grows at the air/growth medium interface provided by the wicking membranes.

15 Figure 14 illustrates further use of the apparatus illustrated in Figure 12. In this arrangement, the apparatus is shown after the growth medium 118 has been replaced by a replacement medium 120, deficient in particular nutrients so as to stimulate secondary 20 metabolism. In this case, the apparatus 100 is tilted such that the replacement medium 120 makes contact with the entire outer membrane 134. Again, the inner and

outer membranes 134, 136 act as wicks, but it is advantageous to have as much of the area of the membranes in contact with the liquid as possible, so as to promote secretion of secondary metabolites into the medium 120.

5

In both Figures 12 and 14, the apparatus can be agitated either by shaking or stirring as indicated by arrows 122, to promote aeration of the medium 118, 120.

10 Figure 15 shows a fifth specific embodiment of the apparatus in accordance with the invention. The apparatus 200 is of similar construction to the apparatus illustrated in Figure 12. To the extent that the apparatus 200 includes a receptacle 210, a lid 212 with 15 associated bore 214 and flange 213, and a foam plug 216, as described with reference to Figure 12, no further description of those parts is necessary. However, the apparatus further includes a fermentation vessel 228 of different construction to the fermentation vessel 200 illustrated in Figure 12. In this case, the vessel 228 is formed with an outer membrane 234 extended substantially down the entire length of the vessel 228

except for a short length at which the vessel is taper-fitted to the flange 213. Furthermore, the outer membrane 234 extends over the opposite end of the vessel 228, which is illustrated dipped in a quantity of a 5 growth medium 218. This provides a large area of membrane for growth of microorganism thereover. As in Figure 12, the outer membrane 234 has an inner membrane 236 laid thereover, on which microorganism can be grown. At the end of the membrane 234 adjacent the portion of 10 the vessel 228 to be taper fitted, the vessel 228 is provided with a radially inwardly extending dam 229.

Figure 16 illustrates the vessel 228 in further detail. The apparatus of Figure 15 can be used to generate 15 mycelial biomass in the same manner as is described in relation to Figure 12. Moreover, the apparatus can be used to stimulate secondary metabolism. Figure 17 illustrates an arrangement whereby the apparatus is being used with replacement medium 220 to stimulate such 20 secondary metabolism. In this case, since the membranes 234, 236 extends substantially longitudinally of the vessel 228, the apparatus 200 can be laid horizontally to

achieve full contact of secondary medium 220 with the membranes 234, 236. This can be advantageous since the apparatus can be stored on a simple rack. The dam 229 prevents ingress of liquid into the vessel 228 when in 5 the horizontal position.

Although the apparatus 200 is shown in a horizontal position in Figure 16, in practice it is unlikely that the quantity of liquid in the receptacle 210 will be 10 exactly the amount to produce the arrangement illustrated in Figure 16. However, the orientation of the apparatus can be deviated slightly from the horizontal in order to achieve as much contact as possible between the membranes 234, 236 and the secondary medium 220.

15

In each of the embodiments described in Figures 12 to 17, it is clear that the microorganism is isolated from the exterior of the fermentation vessel 128, 228, so that spores generated by the microorganism cannot pass into 20 the medium contained in the receptacle 110, 210. Accordingly, secondary metabolites introduced into secondary medium 120, 220 are separated from the biomass

by which they are produced.

By virtue of the isolation, and the definition of an inner chamber within the vessel 128, 228, a pressure differential can be created across the membrane 132, 232 so as to urge medium therethrough. By controlling the pressure differential, or another mechanism such as humidity gradient, the rate at which medium is supplied to the microorganism can be controlled, thereby allowing the control of metabolism, growth and cellular differentiation.

It will be appreciated that in the embodiments illustrated in Figures 12 to 16, the outer membrane 134 can be augmented or replaced by an outer polypropylene sheet, with pore size up to 0.3 microns. Such a sheet 134, 234 would be capable of preventing biomass transfer out of the vessel into the medium contained on the receptacle. In practice, a vessel constructed in that way would still be capable of presenting medium to a microorganism inoculated on the inner membrane 136, since medium would soak through the polypropylene sheet by

virtue of pressure differential, humidity gradient, or both mechanisms. Thereafter, medium which has soaked through will wick up the inner membrane 136, 236 to the microorganism.

5

It will be apparent that the invention is not limited to vessels 128, 228 described above. For example, Figure 18 illustrates a component 300 comprising a wicking material with substantial rigidity, which could be used as a 10 fermentation vessel in the apparatus previously described. In that component, microorganism could be allowed to grow over the entire internal surface area of the component 300, thus maximising the biomass thereof.

15 A further demonstration of the nutrient replacement technique to substantially remove growth medium components and enable the direct detection of secreted secondary metabolites by MALDI-TOF mass spectrometry is demonstrated in the following sixth example of use of the 20 apparatus, with reference to Figures 17 to 20 of the drawings.

Two unidentified fungi F1 and F2 are used in the example. For the purpose of the example, organism F1 is known to produce a family of metabolites called verticillins while F2 is known to produce another family of metabolites 5 called enniatins.

Both organisms are grown in a fermentation apparatus 100 as illustrated in Figure 14, under previously described conditions for fungi using FS as the growth medium and 10 the crystalline sugar mannitol (10 g/l) as the replacement medium. In the apparatus, a precise volume of medium (25 ml) is placed in contact with the maximum surface area of the membrane, as shown in that drawing. The membranes 134, 136 are replaced by a single membrane 15 constructed from hydrophilic polypropylene fibre (Kimberly-Clark) with an open structure which acts to support organism growth but not physically prevent penetration. In each case, the apparatus is inoculated using an agar plug containing actively growing mycelium. 20 The growth phase FS is maintained for 10 days and then incubation of the replacement medium is allowed to proceed for 10 days. The temperature under both phases

of growth is controlled at 22°C.

Despite penetration of the membrane support to the medium side, both fungi remain almost entirely attached, 5 facilitating easy aseptic transfer to a second vessel containing the replacement medium. The fungal mycelium remains attached to the membrane support while incubated on the replacement medium allowing easy separation from the fungal biomass at the end of incubation. The 10 nutrient replacement medium containing secreted fungal metabolites is retained for analysis.

In control experiments run alongside the above described example for reasons of composition, the organisms are 15 allowed to grow on FS medium with no medium replacement, for a period of 20 days. A sample of the FS medium free of any fungal mycelium is retained for analysis.

Experimental and control samples are then analysed by 20 MALDI-TOF mass spectrometry as follows:

300 µl of the experimental samples are dried down under

vacuum and concentrated threefold by resuspending in 100 μ l 50% methanol in deionised water containing 0.1% trifluoroacetic acid. The aqueous control samples are analysed directly without the concentration step. 0.5 μ l 5 of sample is mixed with 0.5 μ l of matrix (20 mg/ml 2,5-dihydroxybenzoic acid in deionised water) on a mass spectrometer slide and allowed to dry. The slide is then inserted into the instrument. The mass spectrometer is operated in reflectron mode with an extraction voltage of 10 40 kV. The laser is tuned to an optimal level for the analysis of each sample.

In the spectra of the experimental samples, peaks corresponding to the verticillins (organism F1) are 15 prominent and clearly identifiable (Figure 19a). A fragment of the particular area of interest of Figure 19a is expanded in Figure 19b.

For example, a peak which is prominent in Figure 19b, has 20 a mass/charge ratio of 755.5 corresponds with verticillin B, potassium adduct ($M_B + 3H + K^+$). Another peak, prominent at a mass/charge ratio of 771.1 corresponds

with verticillin C, sodium adduct ($M_c + 3H + Na^+$). These correspondences are provided in libraries of data which are in the public domain.

5 Similarly, the experimental samples generated from organism F2 are analysed by MALDI-TOF mass spectrometry and identify members of the enniatin family. These are shown in the spectra illustrated in Figures 21a and 21b.

10 As shown in Figure 21b, a peak is prominent at a mass/charge ratio of 663.2. This corresponds with enniatin B, sodium adduct ($M_b + Na^+$). A peak at mass/charge ratio 677.1 corresponds with enniatin B, potassium adduct ($M_b + K^+$), a peak at 691.6 corresponds 15 with enniatin D, potassium adduct ($M_d + K^+$) and a peak at mass/charge ratio of 706.8 corresponds with enniatin A, sodium adduct ($M_a + 2H + Na^+$).

20 The corresponding control samples (Figure 20 for F1 and Figure 22 for F2) generate very poor spectra under MALDI-TOF mass spectrometry. In these spectra, there is no evidence of a peak corresponding to either of the

verticillin (Figure 20) or the enniatin (Figure 22) species identified in respect of the experimental samples.

5 For optimal results in applying MALDI-TOF mass spectrometry to a sample, it is desirable that the sample crystallises with the matrix on the slide prior to analysis. Crystallinity is not apparent on the slides containing control samples which explains the poor 10 analytical results. This problem arises from the higher concentrations of medium components in each control sample, which cause a syrup to be formed when the control sample is dehydrated.

15 It can be seen from the foregoing example that the nutrient replacement process clearly generates samples of fungal origin which can be analysed directly by MALDI-TOF mass spectrometry without extensive pre-preparation.

20 A further example will now be used to demonstrate that the procedures and apparatus are applicable to the secretion of proteins into a "clean" medium, allowing for

ease of isolation. In this example, another unidentified fungus, F3 is grown under identical conditions as F1 and F2 and experimental and control samples analysed by MALDI-TOF mass spectrometry. The spectrum corresponding 5 to the experimental sample is illustrated in Figure 23, and that corresponding to the control sample is illustrated in Figure 24. In the experimental samples, a characteristic peak corresponding to a small unidentified protein with an m/z (mass/charge ratio) of 10 6239.1 is clearly visible (Figure 23). Again, the corresponding control spectrum shown in Figure 24 is poor and no protein peaks are detectable.

The nutrient replacement process therefore provides a 15 means of culturing organisms to produce samples containing secreted proteins which can be detected directly by MALDI-TOF mass spectrometry (a technology used extensively for protein and peptide analysis).
20 Combining the nutrient replacement process with MALDI-TOF analysis therefore enables the direct screening of organisms for secreted protein products. The organisms

may be wild type strains or genetically modified by the insertion of a gene (expressing a known or unknown protein) into a suitable host. The presently described procedures and apparatus allow such protein expression to 5 be conducted and analysis to be applied directly to the generated samples, without the need for intermediate steps to increase the purity or cleanliness of the sample. Purity and cleanliness are concerned with the level of impurities in the sample - the concentration of the 10 desired biochemical in the sample is of less importance than the need to ensure that other chemicals do not prevent operation of or obscure the spectrum of the chemical or chemicals under investigation.

15 Once metabolites have been produced by the methods described above in accordance with the apparatus illustrated in the accompanying drawings, they can be isolated and prepared in accordance with known methods to produce pharmaceuticals for medical or veterinary use, or 20 to produce agrochemicals such as fungicides or other pesticides. Moreover, the metabolites can be extracted to establish their chemical structures, as a precursor to

identify alternative methods of production thereof, such as by non-biological chemical processes.

In particular, samples of secondary metabolites can be 5 produced by methods as described above in accordance with specific embodiments of inventions, for development of new biochemicals, such as pharmaceuticals (both medical and veterinary) and agrochemicals (e.g. pesticides, fungicides, herbicides and growth regulators). A large 10 array of different metabolites can be produced with ease.

Each metabolite can then be tested for efficacy, for instance as a pharmaceutical or agrochemical, and any metabolites demonstrating useful effects can then be selected for further development. Further development 15 includes the steps of identifying a method by which metabolite can be produced for commercial exploitation thereof. This may be by large scale fermentation in accordance with the described procedures, or alternatively it could involve identifying the molecular 20 structure of a metabolite so that it can be synthesised.

It will be appreciated by the reader that the term

metabolite is being used in its broadest sense, i.e. a biochemical the product of a biosynthesis process within, or associated with, a microorganism. In that sense, a metabolite would include one of the secondary products 5 associated with metabolism in a fungus, and may also include metabolic products such as enzymes, proteins and peptides.

CLAIMS:

1. A method of producing a biochemical, comprising the steps of:

5 providing a microorganism on a support; positioning said support such that said microorganism has access to a first medium providing conditions for growth of said microorganism;

10 separating said microorganism from said first medium; and

positioning said support such that said microorganism has access to a second medium providing conditions for biosynthesis of said biochemical by said microorganism.

15 2. A method in accordance with claim 1 including the step of extracting said biochemical from said second medium.

20 3. A method in accordance with claim 1 including the step of extracting said biochemical from biomass of said microorganism.

25 4. A method in accordance with claim 2 or claim 3 including the step of separating said biochemical from an

extract the product of said extracting step.

5. A method in accordance with claim 4 wherein the step of separating said biochemical includes performing high pressure liquid chromatography on said extract.

10 6. A method in accordance with any preceding claim including the step of controlling delivery of said first medium to said microorganism when said microorganism has access thereto.

15 7. A method in accordance with claim 6 wherein said step of controlling delivery of said first medium includes the step of regulating a pressure gradient along which said first medium is delivered.

20 8. A method in accordance with claim 6 or claim 7 wherein said step of controlling delivery of said first medium includes the step of regulating a humidity gradient along which said first medium is delivered.

25 9. A method in accordance with any of claims 6 to 8 wherein said step of controlling delivery of said first medium includes the step of regulating a concentration gradient along which said first medium is delivered.

10. A method in accordance with any preceding claim including the step of controlling delivery of said second medium to said microorganism when said microorganism has access thereto.

5

11. A method in accordance with claim 10 wherein said step of controlling delivery of said second medium includes the step of regulating a pressure gradient along which said second medium is delivered.

10

12. A method in accordance with claim 10 or claim 11 wherein said step of controlling delivery of said second medium includes the step of regulating a humidity gradient along which said second medium is delivered.

15

13. A method in accordance with any one of claims 10 to 12 wherein said step of controlling delivery of said second medium includes the step of regulating a concentration gradient along which said second medium is delivered.

20

14. A method of developing a pharmaceutical product comprising the steps of:

25 performing the method of any one of claims 1 to 13 in respect of a microorganism under investigation;

applying mass spectrometry analysis to a sample generated by the method; and

identifying a biochemical component of the sample for further investigation.

5

15. A method in accordance with claim 14 comprising the step of:

testing the identified biochemical for pharmaceutical efficacy.

10

16. A method in accordance with claim 14 including the step of:

preparing said biochemical for human or animal consumption.

15

17. A method of developing an agrochemical comprising the steps of:

performing the method of any one of claims 1 to 13 in respect of a microorganism under investigation;

20

applying mass spectrometry analysis to a sample generated by the method; and

identifying a biochemical component of the sample for further investigation.

25

18. A method in accordance with claim 17 comprising the

step of:

testing the identified biochemical for agrochemical efficacy.

5 19. A method in accordance with claim 18 including the

step of:

preparing said biochemical for agricultural application.

10 20. A method of producing a pharmaceutical product

including the steps of:

producing a plurality of samples of biochemicals, each sample being produced by means of the method of any one of claims 1 to 13;

15 testing each sample for pharmaceutical efficacy of the biochemical; and

for a sample of a biochemical showing pharmaceutical efficacy, producing and preparing said biochemical for human or animal consumption.

20

21. A method of producing an agrochemical product including the steps of:

producing a plurality of samples of biochemicals, each sample being produced by means of the method of any one of claims 1 to 13;

25

testing each sample for agrochemical efficacy of the biochemical; and

for a sample of a biochemical showing agricultural usefulness, producing and preparing said biochemical for
5 agricultural application.

22. A method in accordance with claim 20 or claim 21
wherein said testing step includes directly applying an
identification analysis method to each sample and
10 thereafter performing efficacy tests on identified
biochemical components of said samples.

23. A method in accordance with claim 22 wherein said
step of applying an identification analysis method
15 comprises applying mass spectrometry analysis to each
sample.

24. A method in accordance with claim 22 wherein said
step of applying an identification analysis method
20 comprises applying chromatographic analysis to each
sample.

25. A method in accordance with any preceding claim
wherein said positioning step places the microorganism
25 with access to a medium providing conditions for a

secondary metabolism pathway to be established, said biochemical being a secondary metabolite of said microorganism.

5 26. Apparatus for producing a biochemical including:
storage means for storing a medium for use by a
microorganism;

10 support means for supporting a microorganism such
that said microorganism has access in use to medium
stored in said storage means, wherein said support means
is separable from medium stored in said storage means in
use.

15 27. Apparatus in accordance with claim 26 including
delivery means for delivering medium from said storage
means to a microorganism supported in use in said support
means.

20 28. Apparatus in accordance with claim 27 wherein said
delivery means defines a capillary pathway for delivery
of medium.

25 29. Apparatus in accordance with claim 27 or claim 28
wherein said support means is arranged to segregate in
use a microorganism supported thereon from medium stored

in said storage means.

30. Apparatus in accordance with any one of claims 27 to 29 wherein said support means includes manipulation means 5 extending out of said storage means for aseptic manipulation of said support means.

31. Apparatus in accordance with claim 30 wherein said manipulation means is integral with said support means.

FIG. 1










FIG. 2**FIG. 3**

3/26

FIG. 4**FIG. 5****FIG. 6**


4/26

FIG. 7a




5/26

FIG. 7b




6/26

FIG. 8a




7/26

FIG. 8b



8/26

FIG. 8C



9/26

C16




FIG. 9a mAU

C17




FIG. 9b mAU

10/26

C19




FIG. 9c

C41





FIG. 9d

11/26

D11


FIG. 10a



12/26


FIG. 10b

D15



13/26


FIG. 10c



14/26

FIG. 11a


E16



15/26

FIG. 11b


E19



16/26

FIG. 11C

E44



17/26

FIG. 13




FIG. 12





FIG. 14



19/26







FIG. 16




20/26

FIG. 17**FIG. 18**

21/26


Organism F1
Cell filtrate, FS, Mann -DHB
%Int. 100% =28 mV[sum= 2876 mV] Profiles 1-100 Smooth Gauss 60 -Baseline 10

FIG. 19a



Organism F1
Cell filtrate, FS, Mann -DHB
%Int. 100% =11 mV[sum= 1164 mV] Profiles 1-100 Smooth Gauss 60 -Baseline 10


FIG. 19b



22/26

FIG. 20

Organism F1
FS Control -DHB
100% = 1 mV [sum = 125 mV] Profiles 1-100 Smooth Gauss 60 -Baseline 10
%Int. 101.0



Organism F2
Cell filtrate, FS, Mann -DHB
%Int. 100% =51 mV[sum= 5125 mV] Profiles 1-100 Smooth Gauss 60 -Baseline 10
104.4

FIG. 21a





FIG. 21b







FIG. 22

24/26

25/26

FIG. 23


Organism F3
Cell filtrate, FS, Mann -DHB
100% =5 mV[sum= 597 mV] Profiles 1-100 Smooth Gauss 60 -Baseline 10
6239.1



26/26

FIG. 24

Organism F3
FS Control-DHB
100% = 0 mV [sum= 91 mV] Profiles 1-100 Smooth Gauss 60 -Baseline 10
%Int. 119.8



INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/01000

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12M1/12 C12M1/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPODOC WPI PAJ TXTE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2 761 813 A (A. GOETZ) 4 September 1956 (1956-09-04)	1,6, 8-10,12, 13,15, 16,20, 25-31 14, 17-19, 21-24
Y	column 2, line 24 -column 3, line 73 column 5, line 21 - line 42; claims; figures 1-6 — —/—	

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

31 May 2000

Date of mailing of the international search report

07/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Coucke, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/01000

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2 923 669 A (E. POITRAS) 2 February 1960 (1960-02-02)	1,6, 8-10,12, 13,15, 16,20, 25-31
Y	the whole document	14, 17-19, 21-24
	column 3, line 50 - line 68	—
X	US 3 448 011 A (RUSSOMANNO ROCCO JOSEPH) 3 June 1969 (1969-06-03)	1,14, 17-19, 21-24, 26,27, 29-31
Y	column 6, line 19 -column 7, line 7; figures	1,14, 17-19, 21-24,26
X	EP 0 236 751 A (SARTORIUS GMBH) 16 September 1987 (1987-09-16) claims; figures	26,27, 29-31
X	US 5 122 470 A (BANES ALBERT J) 16 June 1992 (1992-06-16) claims; figures	26-29
X	US 5 324 657 A (TANNY GERALD B) 28 June 1994 (1994-06-28) claims; figures	26-29
X	PATENT ABSTRACTS OF JAPAN vol. 1996, no. 08, 30 August 1996 (1996-08-30) & JP 08 089231 A (KIKKOMAN CORP), 9 April 1996 (1996-04-09) abstract	26-29
X	US 5 215 920 A (LYMAN GEORGE ET AL) 1 June 1993 (1993-06-01) claims; figures	26,27,29
X	DE 839 245 C (E KANZ) page 4, line 33 - line 45; claims; figure 3	26-31
X	EP 0 390 367 A (STERIS CORP) 3 October 1990 (1990-10-03) figures	26,27,29
X	US 4 772 558 A (HAMMANN RANIER) 20 September 1988 (1988-09-20) figures	26,27, 29-31
	—	—/—

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/01000

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR 2 070 560 A (GUIGAN JEAN) 10 September 1971 (1971-09-10) figures	26, 27, 29, 31
Y	US 5 879 932 A (SPAULDING VINCENT P ET AL) 9 March 1999 (1999-03-09) claims; figures	1, 26
X	US 4 859 586 A (EISENBERG ELIAHU ET AL) 22 August 1989 (1989-08-22) claims; figures	26, 27, 29-31
X	EP 0 581 022 A (DIESSE DIAGNOSTICA) 2 February 1994 (1994-02-02) claims; figures	26, 27, 29-31
Y	-----	1, 14, 17-19, 21-24

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/01000

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 2761813	A	04-09-1956	NONE		
US 2923669	A	02-02-1960	NONE		
US 3448011	A	03-06-1969	NONE		
EP 0236751	A	16-09-1987	DE	3703608 A	13-08-1987
			DE	3744925 C	19-12-1991
			DE	3744926 C	28-11-1991
US 5122470	A	16-06-1992	AU	3865489 A	05-02-1990
			EP	0435871 A	10-07-1991
			JP	4500455 T	30-01-1992
			WO	9000595 A	25-01-1990
US 5324657	A	28-06-1994	IL	101659 A	30-03-1995
			IL	105209 A	31-01-1996
			AT	162927 T	15-02-1998
			CA	2159213 A	13-10-1994
			WO	9422290 A	13-10-1994
			DE	69408447 D	12-03-1998
			EP	0692929 A	24-01-1996
JP 08089231	A	09-04-1996	NONE		
US 5215920	A	01-06-1993	US	5026649 A	25-06-1991
			US	5466602 A	14-11-1995
			CA	1333373 A	06-12-1994
			DE	3686050 A	20-08-1992
			DE	3686050 T	11-03-1993
			EP	0239697 A	07-10-1987
			JP	1815202 C	18-01-1994
			JP	5017830 B	10-03-1993
			JP	62220184 A	28-09-1987
DE 839245	C		NONE		
EP 0390367	A	03-10-1990	US	4885253 A	05-12-1989
			AT	98989 T	15-01-1994
			CA	2010063 A,C	27-09-1990
			DE	69005344 D	03-02-1994
			DE	69005344 T	21-04-1994
			DK	390367 T	14-02-1994
			ES	2047845 T	01-03-1994
			HK	183896 A	11-10-1996
			JP	2286073 A	26-11-1990
			JP	2562221 B	11-12-1996
US 4772558	A	20-09-1988	NONE		
FR 2070560	A	10-09-1971	CA	969118 A	10-06-1975
			CH	554939 A	15-10-1974
			DE	2058300 A	09-06-1971
			GB	1312280 A	04-04-1973
			JP	49006671 B	15-02-1974
			NL	7017605 A,B	11-06-1971
			SE	385714 B	19-07-1976
			US	3796638 A	12-03-1974

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/01000

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5879932	A 09-03-1999	NONE		
US 4859586	A 22-08-1989	CH 671031 A		31-07-1989
		DE 8622419 U		22-01-1987
		FR 2586426 A		27-02-1987
		GB 2182144 A,B		07-05-1987
EP 0581022	A 02-02-1994	IT 226753 Z		01-07-1997
		AT 157395 T		15-09-1997
		DE 69313377 D		02-10-1997
		DE 69313377 T		26-02-1998
		ES 2108786 T		01-01-1998
		GR 3025289 T		27-02-1998
		JP 6078746 A		22-03-1994
		US 5420018 A		30-05-1995